Menu
The first cut-free endoscopic treatment for diabesity, ForePass ® is able to replicate the most common types of metabolic surgery (Roux-en-Y Gastric Bypass, RYGB, BilioPancreatic Diversion, and Sleeve Gastrectomy). The first version of our product is aimed at RYGB.
Only truly effective treatment for diabetes and obesity able to generate 30%+ total body weight loss. Leads to full diabetes, NASH, liver fibrosis, and insulin resistance remission. However, it also leads to 15% complications, including death (0.1-1% with some surgeries).
Widely considered safe, but ineffective on weight loss and diabetes. Unable to generate 15% total body weight loss consistently, let alone the 30% required for Class II and III Obesity.
Semaglutide (e.g. Ozempic)—the gold standard for obesity and diabetes—fails to deliver 15% total body weight loss in 92% of patients. 85% discontinue within 24 months. It shows limited impact on key comorbidities like NASH, liver fibrosis, and insulin resistance. These drugs are especially ineffective for Class II and III obesity (BMI ≥35), where substantial weight loss and disease reversal are most needed.
Designed to replicate metabolic surgery without any cuts to internal organs. As effective on diabetes and obesity as metabolic surgery in animals.
Keyron’s patented ForePass ® device is the first designed to target the root mechanisms of insulin resistance and obesity
ForePass ® replicates the three most common metabolic surgeries without requiring a single cut
Our large animal data was published in Gut, the world’s leading journal in gastroenterology and hepatology, and the official journal of the British Society of Gastroenterology, with an exceptionally high impact factor of 25.8.
Pre-clinical studies have shown that the efficacy of ForePass ® may be unprecedented, and likely even better than Roux-en-Y Gastric Bypass surgery. Our long-term animal data shows (Δ from Baseline vs endoscopic controls):
Conclusion: ForePass ® reduced body weight, glycemia and insulin resistance, and liver fat deposition to the same level of gastric bypass surgery
We demonstrated a full reversal of diabetes and NASH, and weight loss, to levels not statistically different from gastric bypass surgery
Note: ForePass ® was previously named Sleeveballoon.
ForePass ® is an extremely promising technology which may allow us to deliver the same benefits of metabolic surgery but without the complications from a surgical procedure
The rodent data obtained with ForePass shows that the device is expected to reach the same unmatched efficacy of metabolic surgery, primarily a remission of insulin resistance and substantial weight loss.
ForePass could allow many more people to access the efficacy that metabolic surgery is known for. Its elegant anchoring system could ensure the required safety that so many other devices in the space have not been able to achieve
© Copyright Keyron 2025. All Rights Reserved.
